Puig/Coty deal
This article was originally published in The Rose Sheet
Executive Summary
Puig Beauty & Fashion Group will expand its presence in the U.S. through a strategic partnership with Coty, firms announce Feb. 24. Effective July 1, Coty Prestige will take over "back office services, logistics, and its strong commercial platform, while Puig will manage the development of its brand portfolio through its own marketing team," companies note. "We have had for some time an ambition to make further inroads into the U.S. market, and this alliance is an important part of realizing that goal," Puig Beauty & Fashion Group CEO Marc Puig says, adding "We are confident the Coty organization is the best possible partner to help us understand the retail landscape and work with us towards the future success for our brands." Barcelona company's fragrance portfolio includes prestige scents under Carolina Herrera, Prada, Nina Ricci, Paco Rabanne and Comme des Garcons...
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.